Is Accuray, Inc. overvalued or undervalued?

As of 10 June 2025, the valuation grade for Accuray, Inc. has moved from attractive to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios include a Price to Book Value of 2.68, an EV to EBITDA of 14.26, and a ROCE of 6.87%. Notably, Accuray's P/E ratio is not applicable due to its loss-making status, which further emphasizes its valuation challenges.
In comparison to peers, Accuray's EV to EBITDA ratio of 14.26 is significantly higher than Tactile Systems Technology, Inc. at 6.29 and Utah Medical Products, Inc. at 5.84, suggesting that Accuray is priced at a premium relative to these companies. The recent stock performance has also been underwhelming, with a year-to-date return of -36.87%, contrasting sharply with the S&P 500's 2.44% return, reinforcing the notion that the stock may be overvalued in the current market environment.